Competitor Landscape: HIV

Competitor Landscape: HIV

Summary

"Competitor Landscape: HIV", briefings contain evaluations of ongoing development activities within the Human Immunodeficiency Virus (HIV) disease market, together with analysis of current & potential future product positioning.

Key Highlights from the report -

• Doravirine (approved in the US in Aug 2018) provides a tolerable NNRTI option with a high barrier to resistance, and is expected be used as part of multi-pill triple combinations where it may replace older NNRTIs.


• If approved, ibalizumab would be the first biologic and first long-acting HIV drug in the EU, and would provide an option for patients with multidrug-resistant HIV infection which represents a population with a high unmet need.


• While Frontier Biotech received China approval for albuvirtide for the treatment of HIV in Jun 2018, its FDA approved IND for a Phase II trial of albuvirtide + 3BNC117 is the first indication of clinical activity in the US.

Competitor Landscape: Human Immunodeficiency Virus (HIV) report comprises five key sections.

Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted the HIV landscape.

Landscape Updates -

• ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.


• Timeline forecasts for each approved product’s lifecycle management initiatives.


• ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies.

Pipeline Landscape -

• An overview of pipeline candidates, containing snapshots of current development status.


• Expected drug-specific events & milestones until YE 2021.

Approved Product Landscape: An overview of approved drugs, containing snapshots of current development status.

Appendix -

• Current early stage HIV pipeline & candidate ‘Watch List’.


• Timeline assumptions, including standard assumptions & drug-specific assumptions.

Scope

• The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)


• Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix


• Forecasts are presented in pipeline forecast figures & detailed tables


• ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to Buy

• Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher


• Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market


• Reviews ongoing lifecycle management strategies for existing players in the market


• A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.